NCT02598193已完成4 期
An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet®) in Combination With Nintedanib (Ofev®) in Patients With Idiopathic Pulmonary Fibrosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 89
- 试验地点
- 38
- 主要终点
- Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day
研究概览
简要总结
This clinical study will evaluate the safety and tolerability of combination treatment of nintedanib and pirfenidone in participants with IPF. Eligible participants must have received pirfenidone for at least 16 weeks on a stable dose. Nintedanib will be added on Day 1 of the study as a combination treatment for IPF for 24 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who are on pirfenidone for at least 16 weeks and on a stable dose (defined as 1602-2403 mg/day) for at least 28 days at the start of Screening; the dose must be expected to remain in that range throughout the study
- •Documented diagnosis of IPF, per the Investigator per using the criteria of the 2011 American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Latin American Thoracic Association guidelines
- •Participants with percent predicted forced vital capacity (FVC) more than or equal to (>=) 50 percent (%) and percent predicted carbon monoxide diffusing capacity (DLco) >=30% at Screening
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of less than (<) 1% per year, during the treatment period and for at least 3 months after the final Follow-up Visit
- •For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm during the treatment period and for at least 4 months after the final Follow-up Visit
排除标准
- •Participants with clinical evidence of active infection
- •Participant with any new or ongoing moderate or severe adverse reaction considered by the Investigator to be related to pirfenidone, or an pirfenidone treatment interruption in the 28 days before the start of Screening
- •Any condition that is likely to result in death in the 12 months after the start of Screening
- •Lung transplantation anticipated or any planned significant surgical intervention
- •Known hypersensitivity to the active substance or any excipient of either pirfenidone or nintedanib
- •Mild (Child Pugh A), moderate (Child Pugh B), or severe (Child Pugh C) hepatic and/or severe renal impairment
- •History of gastrointestinal (GI) tract perforation, unstable or deteriorating cardiac or pulmonary disease (other than IPF), long QT syndrome, alcohol or substance abuse in the 2 years before the start of screening, use of any tobacco product in the 12 weeks before the start of screening
- •Bleeding risk
- •Use of Cytochrome P450 (CYP) 1A2 (CYP1A2) inhibitors (for example, fluvoxamine, enoxacin) and/or use of inhibitors of P-glycoprotein (for example, ketoconazole, erythromycin) or CYP3A4 (for example, ketoconazole, erythromycin) or their inducers (for example, rifampicin, carbamazepine, phenytoin, St John's wort) in the 28 days before the start of Screening
- •Pregnancy or lactation
- •Hypersensitivity to peanuts and/or soy
- •Use of pirfenidone and/or nintedanib in a clinical study protocol in the 28 days before the start of screening
研究组 & 干预措施
Pirfenidone+Nintedanib
Experimental
Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
干预措施: Nintedanib (Drug)
Pirfenidone+Nintedanib
Experimental
Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
干预措施: Pirfenidone (Drug)
结局指标
主要结局
Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day
时间窗: Week 24
次要结局
- Total Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments(Baseline up to Week 24)
- Percentage of Participants With Adverse Events and Serious Adverse Events(Baseline up to Week 28)
- Total Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib(Baseline up to Week 24)
- Percentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit(Baseline up to Week 24)
研究者
研究点 (38)
Loading locations...
相似试验
终止
1 期
Study of Nintedanib and Chemotherapy for Advanced Pancreatic CancerCancer of PancreasNCT02902484University of Texas Southwestern Medical Center14
尚未招募
2 期
Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint InhibitorsHepatocellular CarcinomaNCT06031480Shanghai Zhongshan Hospital55
已完成
1 期
Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma HistologyAdenocarcinoma of the LungNCT04046614AIO-Studien-gGmbH56
进行中（未招募）
1 期
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AFibroblast Growth Factor Basic Form MeasurementFLT3 Internal Tandem DuplicationRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaNCT03513484Northwestern University44
进行中（未招募）
不适用
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCCHepatocellular CarcinomaNCT06519721RenJi Hospital15